The research-based pharmaceutical industry, represented by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), welcomes the assessment of the global response to the 2009 H1N1 pandemic conducted by the independent International Health Regulations (IHR) Review Committee, whose final report was the subject of a resolution 1 approved by the World Health Assembly. The pandemic...
Read moreAs one of the 189 nongovernmental organizations (NGOs) in official relations with the World Health Organization (WHO), and in line with WHO principles governing relations with NGOs, representatives of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) will be present to listen to the proceedings of the 64th World Health Assembly (WHA). The IFPMA...
Read moreThe results of AIPM research show an insufficient level of diagnosis and low awareness of their personal health April 26, 2011, Moscow –Today The Association of International Pharmaceutical Manufacturers (AIPM) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) presented the survey entitled Population Attitude to Personal Health: Perception of Health, Understanding of Risk Factors, Morbidity and Mortality, conducted in Russia from January, 2011 to April, 2011. The findings show...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) welcomes the outcome of the WHO Open-Ended Working Group of Member States on Pandemic Influenza Preparedness (OEWG/PIP). The Working Group has reached a decision that will result in an effective global system to prepare for potential future influenza pandemics, recognizing a shared responsibility to help secure...
Read moreThe International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today gives its support to the 2011 WHO World Health Day, which this year takes as its theme Anti-Microbial Resistance (AMR) and raises awareness of the problem of antibiotics losing their effectiveness over time as bacteria naturally evolve and mutate to become resistant to drug treatments....
Read moreThe global research-based pharmaceutical industry represented by the IFPMA is providing significant funds to relief organisations following the major earthquake that struck Japan on 11 March 2011. The total cash value of assistance provided so far by IFPMA member companies already amounts to over USD 40 million, and several companies have also donated medicines and...
Read moreA paper published today by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), which represents the R&D-based pharmaceutical industry worldwide, documents the growing trend of technology transfer in medicines and vaccines. It also identifies the critical enabling conditions which allow technology transfer to contribute successfully to global economic development and health. Mr. Eduardo Pisani,...
Read moreThe International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today expressed the research-based pharmaceutical industry’s support for calls to extend the deadline for Least-Developed Countries to comply with the provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Mr. David Brennan, President of the IFPMA and CEO of AstraZeneca, said: “We recognize...
Read more